कृपया अन्य खोज का प्रयास करें
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, and diagnostic companies. The company has a collaboration partnership with Celonic AG. The company was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Simon Gordon Douglas | 62 | 2011 | Non-Executive Chairman |
Adrian Robert Kinkaid | 56 | 2022 | CEO & Director |
Stephen Barry Smyth | 48 | 2023 | Company Secretary, Interim CFO & Director |
Richard John Buick | 47 | 2011 | Chief Scientific Officer & Director |
Terence H. Rabbitts | - | 2022 | Member of Scientific Advisory Panel |
Matthew Paul Baker | 52 | 2022 | Member of Scientific Advisory Panel & Independent Non-Executive Director |
Charlotte Deane | - | 2022 | Member of Scientific Advisory Panel |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है